{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    49,
    50,
    51,
    52,
    53,
    55,
    56,
    57,
    58,
    59,
    60,
    61,
    62,
    64,
    65,
    68,
    69,
    70,
    77,
    78,
    87,
    89,
    90
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "Date of subject randomization",
        "anchorType": "Randomization",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Day of \nRandomization"
      },
      {
        "id": "anchor_2",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "baseline visit"
      },
      {
        "id": "anchor_3",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "screening period"
      },
      {
        "id": "anchor_4",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Informed Consent"
      },
      {
        "id": "anchor_5",
        "definition": "Procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_5",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_daily_6",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_30",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "QD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "BID"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "run-in period"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "run-in phase"
      },
      {
        "id": "rep_window_14",
        "type": "Continuous",
        "sourceText": "Treatment \nPhase"
      },
      {
        "id": "rep_window_15",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_16",
        "type": "Continuous",
        "sourceText": "treatment \nPhase"
      },
      {
        "id": "rep_window_17",
        "type": "Continuous",
        "sourceText": "treatment Phase"
      },
      {
        "id": "rep_window_20",
        "type": "Continuous",
        "sourceText": "treatment phase"
      },
      {
        "id": "rep_window_25",
        "type": "Continuous",
        "sourceText": "posttreatment period"
      },
      {
        "id": "rep_window_26",
        "type": "Continuous",
        "sourceText": "8 hours before"
      },
      {
        "id": "rep_window_27",
        "type": "Continuous",
        "sourceText": "30 days before"
      },
      {
        "id": "rep_llm_1",
        "type": "Daily",
        "startOffset": "P0D",
        "endOffset": "null",
        "interval": "P1D",
        "exitCondition": "End of treatment period",
        "sourceText": "DOSAGE AND ADMINISTRATION ... Study Drugs"
      },
      {
        "id": "rep_llm_2",
        "type": "Continuous",
        "startOffset": "null",
        "endOffset": "null",
        "interval": "null",
        "exitCondition": "null",
        "sourceText": "throughout treatment"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "PRETREATMENT_PHASE",
          "SCREENING",
          "DOUBLE_BLIND_TREATMENT_PHASE",
          "POST_TREATMENT_FOLLOW_UP",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Randomization",
          "Post-Treatment Follow-up",
          "Screening",
          "End of Study",
          "Baseline",
          "Day 1",
          "Double-Blind Treatment Visits"
        ],
        "sourceText": "[{'condition': 'Subject unable to attend scheduled visits', 'path': ['POST_RANDOMIZATION_FOLLOW_UP_FOR_PARTICIPANTS_UNABLE_TO_ATTEND_SCHEDULED_VISITS']}, {'condition': 'Subject experiences primary or secondary composite endpoint events', 'path': ['REPORTING_ADJUDICATION_OF_EVENTS']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood \nCollection",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Recurring",
        "rationale": "SINGLE signals: 1; RECURRING signals: 2"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Event",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Laboratory Tests",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Glucose Monitoring",
        "executionType": "Single",
        "rationale": "SINGLE signals: 3; RECURRING signals: 1"
      },
      {
        "activityId": "Drug Administration",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Diary",
        "executionType": "Recurring",
        "rationale": "SINGLE signals: 1; RECURRING signals: 5"
      },
      {
        "activityId": "Screening Assessment",
        "executionType": "Single",
        "rationale": "The screening phase is a one-time assessment to determine eligibility prior to randomization."
      },
      {
        "activityId": "Renal and Cardiovascular Outcome Monitoring",
        "executionType": "Single",
        "rationale": "The study is described as 'event-driven,' requiring continuous monitoring for outcomes over the entire duration of the trial."
      },
      {
        "activityId": "Scheduled Study Visits",
        "executionType": "Single",
        "rationale": "The 'Time and Events Schedule' indicates data collection occurs at multiple scheduled intervals throughout the study."
      },
      {
        "activityId": "Safety Monitoring for Renal Function",
        "executionType": "Single",
        "rationale": "Safety protocols for renal impairment (e.g., eGFR <30 mL/min/1.73m2) involve conditional actions based on specific clinical thresholds."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "a. EOS = end-of-study; EOT = end-of-treatment; EW=early withdrawal; HbA1c =hemoglobin A1c; CBC = complete blood count; SMBG = self-monitored blood glucose; TC = telephone contact.",
        "footnoteId": "fn_1",
        "structuredCondition": "definition_mapping(EOS, EOT, EW, HbA1c, CBC, SMBG, TC)",
        "appliesToActivityIds": [
          "EOS",
          "EOT",
          "EW",
          "HbA1c",
          "CBC",
          "SMBG",
          "TC"
        ],
        "sourceText": "a. EOS = end-of-study; EOT = end-of-treatment; EW=early withdrawal; HbA1c =hemoglobin A1c; CBC = com"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "general",
        "text": "b. Subjects who fail protocol-specified screening criteria for study entry may be rescreened at the discretion of the investigator.",
        "footnoteId": "fn_2",
        "structuredCondition": "if(fail_screening, allow_rescreening(investigator_discretion))",
        "appliesToActivityIds": [
          "Screening"
        ],
        "sourceText": "b. Subjects who fail protocol-specified screening criteria for study entry may be rescreened at the "
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_after",
        "text": "c. At Week 39 and at the midpoint between office visits after Week 52, telephone contact will be made to check the subject's status.",
        "footnoteId": "fn_3",
        "structuredCondition": "schedule(W39, midpoint(office_visits, >W52))",
        "appliesToActivityIds": [
          "Telephone contact"
        ],
        "sourceText": "c. At Week 39 and at the midpoint between office visits after Week 52, telephone contact will be mad"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_at",
        "text": "d. This visit will occur at Week 52, 104, 156, 208, and 260.",
        "footnoteId": "fn_4",
        "structuredCondition": "visit_weeks([52, 104, 156, 208, 260])",
        "appliesToActivityIds": [
          "Visit"
        ],
        "sourceText": "d. This visit will occur at Week 52, 104, 156, 208, and 260."
      },
      {
        "id": "fn_cond_5",
        "conditionType": "timing_at",
        "text": "e. This telephone contact will occur at Week 39, 65, 91, 117, 143, 169, 195, 221, 247, and 273.",
        "footnoteId": "fn_5",
        "structuredCondition": "telephone_contact_weeks([39, 65, 91, 117, 143, 169, 195, 221, 247, 273])",
        "appliesToActivityIds": [
          "Telephone contact"
        ],
        "sourceText": "e. This telephone contact will occur at Week 39, 65, 91, 117, 143, 169, 195, 221, 247, and 273."
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_at",
        "text": "f. This visit will occur at Week 26, 78, 130, 182, 234 and 286.",
        "footnoteId": "fn_6",
        "structuredCondition": "visit_weeks([26, 78, 130, 182, 234, 286])",
        "appliesToActivityIds": [
          "Visit"
        ],
        "sourceText": "f. This visit will occur at Week 26, 78, 130, 182, 234 and 286."
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "g. End-of-treatment/early withdrawal evaluations will be performed when the double-blind treatment phase is ended.",
        "footnoteId": "fn_7",
        "structuredCondition": "timing.after(double_blind_treatment_end)",
        "appliesToActivityIds": [
          "End-of-treatment evaluations",
          "Early withdrawal evaluations"
        ],
        "sourceText": "g. End-of-treatment/early withdrawal evaluations will be performed when the double-blind treatment p"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "timing_after",
        "text": "h. A telephone follow-up contact will be conducted for all subjects approximately 30 days (+/- 12 days) after the last dose.",
        "footnoteId": "fn_8",
        "structuredCondition": "timing.after(last_dose, P30D, window(P12D))",
        "appliesToActivityIds": [
          "Telephone follow-up contact"
        ],
        "sourceText": "h. A telephone follow-up contact will be conducted for all subjects approximately 30 days (+/- 12 da"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Composite Endpoint",
        "endpointType": "Primary",
        "inputs": [
          "ESKD",
          "Serum Creatinine",
          "Renal Death",
          "CV Death"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "End of Study"
        },
        "algorithm": "COUNT(subjects WITH (ESKD == TRUE OR doubling_of_serum_creatinine == TRUE OR renal_death == TRUE OR CV_death == TRUE))",
        "successCriteria": "Statistically significant reduction in the hazard ratio compared to placebo",
        "sourceText": "9.2. Reporting/Adjudication of Events in the Primary and Secondary Composite Endpoints and Other Events for Adjudication"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Analyses",
        "endpointType": "Secondary",
        "inputs": [
          "Primary Composite Endpoint events",
          "CV Death",
          "Non-fatal MI",
          "Non-fatal Stroke",
          "Hospitalization for Heart Failure"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "End of Study"
        },
        "algorithm": "Hierarchical testing of composite CV outcomes and individual components",
        "successCriteria": "P-value < 0.05 following multiplicity adjustment",
        "sourceText": "11.3.2. Secondary Efficacy Analyses"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Change from Baseline in Albumin/Creatinine Ratio",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Albumin",
          "Creatinine"
        ],
        "derivationRule": "post_baseline_value - baseline_value",
        "baselineDefinition": "Not explicitly defined in text provided",
        "baselineVisit": "Baseline",
        "analysisWindow": "Through 01 July 2012",
        "imputationRule": "Not specified in text provided",
        "unit": "Not specified"
      },
      {
        "id": "dv_2",
        "name": "Mean Change from Baseline in eGFR",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "eGFR"
        ],
        "derivationRule": "post_baseline_value - baseline_value",
        "baselineDefinition": "Not explicitly defined in text provided",
        "baselineVisit": "Baseline",
        "analysisWindow": "Over time (within 2 days after last study medication)",
        "imputationRule": "Not specified in text provided",
        "unit": "mL/min/1.73m2"
      },
      {
        "id": "dv_3",
        "name": "Sustained Doubling of Serum Creatinine",
        "variableType": "Composite",
        "sourceVariables": [
          "Serum Creatinine"
        ],
        "derivationRule": "Post-baseline serum creatinine value >= 2 * baseline average determination, sustained over time",
        "baselineDefinition": "Average of multiple baseline values (baseline average determination)",
        "baselineVisit": "Pre-randomization",
        "analysisWindow": "Up to GTED",
        "imputationRule": "Not specified in text provided",
        "unit": "mg/dL or umol/L"
      },
      {
        "id": "dv_4",
        "name": "Time to first occurrence of ESKD, doubling of serum creatinine, and renal or CV death",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Randomization Date",
          "ESKD Date",
          "Serum Creatinine Doubling Date",
          "Renal Death Date",
          "CV Death Date"
        ],
        "derivationRule": "min(ESKD_date, Doubling_Creatinine_date, Renal_Death_date, CV_Death_date) - Randomization_date",
        "baselineDefinition": "Date of Randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "Randomization to GTED",
        "imputationRule": "Censoring at GTED or last known event-free date",
        "unit": "Days"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Pretreatment Phase",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Pretreatment Phase",
        "Screening",
        "Double Blind Treatment Phase",
        "Post Treatment Follow Up",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Pretreatment Phase",
          "toState": "Screening",
          "trigger": "Progress to Screening"
        },
        {
          "fromState": "Screening",
          "toState": "Double Blind Treatment Phase",
          "trigger": "Progress to Double Blind Treatment Phase"
        },
        {
          "fromState": "Double Blind Treatment Phase",
          "toState": "Post Treatment Follow Up",
          "trigger": "Progress to Post Treatment Follow Up"
        },
        {
          "fromState": "Post Treatment Follow Up",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Pretreatment Phase",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "Double Blind Treatment Phase",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        },
        {
          "fromState": "Post Treatment Follow Up",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Pretreatment Phase": "PRETREATMENT_PHASE",
        "Screening": "SCREENING",
        "Double Blind Treatment Phase": "DOUBLE_BLIND_TREATMENT_PHASE",
        "Post Treatment Follow Up": "POST_TREATMENT_FOLLOW_UP",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_llm_1",
        "treatmentName": "Canagliflozin",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 100.0,
            "unit": "mg",
            "description": "investigational product dose"
          }
        ],
        "durationDescription": "Event-driven",
        "doseModifications": [
          "Safety in renal impairment population monitored (Section 1.1.2.5.3)"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Placebo",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "durationDescription": "Event-driven"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_llm_1",
        "visitName": "Prescreening",
        "targetDay": -180,
        "windowBefore": 0,
        "windowAfter": 180,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Pretreatment"
      },
      {
        "id": "visit_2",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "epoch": "Pretreatment",
        "sourceText": "12 months of screening, or an active skin ulcer, osteomyelitis, gangrene, or critical ischemia of the lower extremity within 6 months of screening. Rationale: Clarify therapy reporting for subjects wh"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "1.1.2.5.1 Overall Safety; 6.1 Study Drug; 12 Adverse Events Reporting;"
      },
      {
        "id": "visit_3",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "endpoints. Lastly, if determined medically necessary, cautionary post-baseline use of mineralocorticoid antagonist (MRA) (according to local label) will be permitted to allow subjects requiring treatm"
      },
      {
        "id": "visit_7",
        "visitName": "end of treatment",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "end of treatment/final on-site visit, 30 day telephone follow-up contact and the actual GTED. Time and Events"
      },
      {
        "id": "visit_10",
        "visitName": "end of study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "Duration of study (from first subject randomized to last end of study visit): estimated to be 60 months. Primary Efficacy Analysis"
      },
      {
        "id": "visit_4",
        "visitName": "Randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "Double-Blind Treatment",
        "sourceText": "Randomization); 4.2. Inclusion Criteria (Criterion #2);"
      },
      {
        "id": "visit_8",
        "visitName": "Week 3",
        "targetDay": 15,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 8,
        "targetWeek": 3,
        "sourceText": "After randomization, subjects will return to the clinic at Week 3, Week 13, Week 26, and every 26 weeks thereafter for laboratory assessments, concomitant medication review, adverse event collection a"
      },
      {
        "id": "visit_11",
        "visitName": "Week 13",
        "targetDay": 85,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "targetWeek": 13,
        "sourceText": "Week 13 Week 26 Week 39"
      },
      {
        "id": "visit_12",
        "visitName": "Week 26",
        "targetDay": 176,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "targetWeek": 26,
        "sourceText": "Week 26 Week 39 (TC) c"
      },
      {
        "id": "visit_9",
        "visitName": "Week 39",
        "targetDay": 267,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "targetWeek": 39,
        "sourceText": "determination of clinical endpoints. At Week 39 and at the midpoint between office visits after Week 52, telephone contact will be made to check the subject status, including discussing study diary en"
      },
      {
        "id": "visit_13",
        "visitName": "Week 52",
        "targetDay": 358,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "targetWeek": 52,
        "sourceText": "Week 52 and at 52- week"
      },
      {
        "id": "visit_6",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 13,
        "sourceText": "Follow-up; 10.1. Subject Completion; Clarified the process of announcement of the predicted Global Trial End Date (GTED),"
      },
      {
        "id": "visit_14",
        "visitName": "Week 65",
        "targetDay": 449,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "targetWeek": 65,
        "sourceText": "Week 65 and at 26- week"
      },
      {
        "id": "visit_15",
        "visitName": "Week 78",
        "targetDay": 540,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 15,
        "targetWeek": 78,
        "sourceText": "Week 78 and at 52- week"
      },
      {
        "id": "visit_16",
        "visitName": "Week 104",
        "targetDay": 722,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 16,
        "targetWeek": 104,
        "sourceText": "to Week 104 were seen in the lumbar spine (a cancellous bone region), femoral neck (a mixed cancellous and cortical bone region), and distal forearm. A decrease in BMD from baseline to Week 104 in the"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "Stratified block randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_llm_1",
          "name": "eGFR category",
          "categories": [
            "30 to <60 mL/min/1.73m2",
            "60 to <90 mL/min/1.73m2"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "JNJ-28431754 (canagliflozin)\nClinical Protocol 28431754DNE3001 - Amendment INT-6\n11\nStatus: Approved, Date: 06 September 2017\nApplicable Section(s)\nDescription of Change(s)\nSynopsis (Secondary \nObject"
    }
  }
}